Backgound. Species of the Leishmania Viannia (L. V.) subgenus harbor the double-stranded Leishmania RNA virus 1 (LRV-1), previously identified in isolates from Brazil and Peru. Higher levels of LRV-1 in metastasizing strains of L. V. guyanensis have been documented in both human and murine models, and correlated to disease severity.
Leishmaniasis is a neglected tropical disease with >1.5 million cases annually and 350 million people living in endemic areas such as Central and South America, the Indian subcontinent, Middle East, and North Africa [1, 2] . Transmitted by the female Lutzomyia and Phlebotomus species sandflies, Leishmania species are intracellular parasites that primarily infect macrophages [3] . Clinical presentations vary from ulcerative lesions of cutaneous leishmaniasis (CL), destruction of the mucosal membranes of mucosal or mucocutaneous leishmaniasis (ML), or the potentially fatal visceral leishmaniasis (VL) that invades the internal organs [1, 2, 4] . Both CL and ML identified in Latin America are categorized as American tegumentary leishmaniasis (ATL). Leishmania species parasites exist in 2 developmentally distinct stages: flagellated promastigotes in the gut of the sandfly and intracellular amastigotes upon internalization by macrophages [5] . Within the phagolysosome of the macrophage, amastigotes are either killed by host immune responses, or persist and proliferate via immune subversion, thus propagating infection [6, 7] .
Parasitological factors play an essential role in successful infection and proliferation of the parasite. One such factor may be the presence of Leishmania RNA virus 1 (LRV-1), found in metastasizing strains of the Leishmania Viannia (L. V.) subgenus, which appears to promote parasitic persistence in ATL [8] . LRV-1 is a double-stranded RNA virus previously identified in strains of L. V. guyanensis and L. V. braziliensis in South America [8, 9] . It is believed that 10%-15% of patients with CL, particularly those infected with L. V. braziliensis, go on to develop ML, and 20%-25% of L. V. braziliensis or L. V. guyanensis isolates from Brazil and Peru harbor LRV-1 [1, 8, 9] . LRV-1 is hypothesized to subvert the protective T-helper 1 (Th1) predominant response of self-healing CL [8, 10] . A murine model of ATL wherein LRV-1 was associated with a mixed Th1/ T-helper 2 (Th2) phenotype, highlighted by increases in the Th1 biomarkers tumor necrosis factor alpha (TNF-α), CCCL5, and CXCL10, and the Th2 cytokine interleukin (IL) 6, established this altered expression to occur via the Toll-like receptor 3 (TLR3) pathway [8] . Since this initial murine model, macrophages infected with other Viannia strains harboring LRV-1 were also shown to induce greater expression of a number of proinflammatory cytokines and chemokines [11] [12] [13] .
Human and mouse models have demonstrated that resistance to leishmanial infection and self-healing skin lesions is associated with the development of a robust Th1 response, characterized by expression of interferon (IFN) γ, IL-1, TNF-α, CXCL10, and CCL5, while susceptibility and parasite persistence is associated with a predominant Th2 response, characterized by expression of IL-4, IL-5, and IL-6 [14] [15] [16] [17] . The detoxification of reactive oxygen species (ROS) by the copper-zinc superoxide dismutase (CuZn-SOD) enzyme further facilitates parasite persistence in the macrophage vacuole [13, [16] [17] [18] . Thus, it is possible to characterize the "immunophenotype" of macrophages by measuring the expression of these Th1 and Th2 biomarkers. To better understand the potential role of LRV-1 in the pathogenesis of ATL, an in vitro human macrophage model was established, and the immunophenotypes of macrophages infected by strains of LRV-1-positive (LRV-1 + ) and LRV-1-
guyanensis, and L. V. panamensis were evaluated.
METHODS

Ethics Approval
Approval for this study was obtained from the Ethics Review Board of Public Health Ontario (code number 2015-048.01).
Clinical Specimen Collection
Unique cultured isolates of Leishmania species were identified from the Public Health Ontario Laboratory between 2012 and 2016, and retrieved from our biobank. Biobanked clinical isolates of Leishmania species and ATCC strains were subjected to Leishmania species confirmation and identification, following clinical testing that included microscopy examination by certified medical laboratory technologists.
Leishmania Species Identification and Confirmation
DNA was extracted using QIAamp DNA Mini Kit Blood (Qiagen). Leishmania genus 18S real-time polymerase chain reaction (qPCR) was performed as previously described [19] . Species identification included analysis of the internal transcribed spacer (ITS) 1, ITS2, cysteine proteinase B (CPB), heat shock protein 70 (HSP70), and mannose phosphate isomerase (MPI) by PCR, restriction fragment length polymorphism (RFLP) analysis, and Sanger sequencing [20, 21] . PCR-RFLP analysis of the ITS1 region can only differentiate L. V. braziliensis from the other species within the Viannia subgenus (L. V. guyanensis, L. V. peruviana, L. V. panamensis, L. V. lainsoni). Thus, PCR-RFLP and sequencing analysis of the CPB, HSP70, MPI, and ITS2 regions were required to differentiate species within the Leishmania Viannia subgenus complex, and to provide a confirmation of the species identified in the initial ITS1 assay. Purified PCR product was used for Sanger sequencing as per Big Dye protocol (Life Technologies). Sequence products were purified and analyzed using the Applied Biosystems 3130xl Genetic Analyzer. Data were standardized using the Sequencing Analyzer program and the BLAST search engine was used to analyze sequences.
Clinical Phenotype of Source Patients
Unique clinical cultures that were identified from de-identified clinical data of source patients were stratified into "severe" and "nonsevere" phenotypes, where a severe phenotype was defined as ulcers with associated erythema, purulent exudate, pain, and/ or lymphatic involvement (eg, inflammatory ulcers); or multifocal/disseminated disease (ulcers in ≥2 anatomic sites and ≥4 in number). A nonsevere phenotype was defined as localized cutaneous ulcers <4 in number.
Macrophage Differentiation and Infection
Macrophage Differentiation
ATCC U937 CRL-1593.2 suspension cells stored in liquid nitrogen were thawed and cultured in RPMI 1640 media (catalog number A1049101, Thermo Fisher Scientific, Carlsbad, California) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) (catalog number 10082-139, Thermo Fisher Scientific) and 1× penicillin/streptomycin (catalog number 15140-122, Thermo Fisher Scientific) at 37°C and 5% carbon dioxide. Cells were maintained at a concentration between 1 × 10 5 and 2 × 10 6 cells/mL and assessed using the Trypan blue exclusion test. U937 monocytes were differentiated into macrophages by resuspending 5 × 10 5 cells/mL of monocytes in RPMI-1640 supplemented with 50 ng/mL phorbol myristate acetate. One milliliter of monocytes was plated on removable glass cover slips onto 24-well plates and allowed to differentiate for 72 hours. Differentiated cells were identified by the presence of pseudopodia and adherence to the plate surface, while nonadherent undifferentiated monocytes were washed away with RPMI 1640 media [22] [23] [24] . Differentiated cells were released from the cover slip using 0.05% Trypsin-ethylenediaminetetraacetic acid (Life Technologies) and a cell count was performed.
Leishmania Strains
The following cultures were confirmed and identified: ATCC strains of L. V. braziliensis ATCC 50135 LRV- 
Infection
Macrophages were infected with promastigotes at a multiplicity of infection (MOI) of 10:1 (parasite: macrophage) in triplicate. Prior to addition to the 24-well plates, promastigotes were centrifuged at 1000 rpm for 5 minutes and the cell pellet was resuspended with fresh RPMI 1640 medium supplemented with 10% FBS. Subsequently, the plates were placed in an incubator set at 37°C and 5% carbon dioxide. Supernatant was collected at 24 and 48 hours. Each sample was centrifuged at 4000 rpm for 5 minutes to pellet cells and debris, and the supernatant was collected, aliquoted, and stored at -80°C prior to commercial enzyme immunoassay (EIA). After supernatant removal, macrophages were washed with phosphate-buffered saline, fixed with methanol, and Giemsa stained (5 minutes in Giemsa stain followed by 5 minutes in Giemsa buffer on a rocker set at 100 rpm). Cover slips were then removed and mounted upside down onto microscope slides using Eukitt mounting media. Slides were visualized under a microscope, to confirm MOI and the presence of amastigotes.
Analysis of Cytokines and Chemokines by EIA
Supernatants were thawed, brought to room temperature, and analyzed using EIA kits for: IL-1β (catalog number HSLB00C), IL-5 (catalog number D5000B), IL-4 (catalog number HS400), IL-6 (catalog number HS600B), IL-12 (catalog number HS120), CXCL10 (catalog number DIP100), CCL5 (catalog number DRN00B), and TNF-α (catalog number HSTA00D) (R&D Systems, Minneapolis, Minnesota); IFN-β (catalog number 41410, PBL Assay Science, Piscataway Township, New Jersey); inducible nitric oxide synthetase (iNOS) (catalog number E-EL-H0753, Elabscience, WuHan, China); and SOD (catalog number ALX-850-033, Enzo Life Sciences, Farmingdale, New York) according to protocols provided by the manufacturer and read on a Synergy Plate Reader (Biotek Instruments, Winooski, Vermont). Concentrations were calculated according to a standard curve generated using the Gen5 Data Analysis Software (Biotek Instruments). EIAs were performed using technical triplicates on each biological triplicate.
Statistical Analysis
Statistical analyses were conducted using GraphPad Prism 6 version 6.07 software (GraphPad Software Inc, La Jolla, California). Mean cytokine and chemokine concentrations were calculated for each strain, by species, and LRV-1 status and compared using unpaired t tests and analysis of variance. The analysis was conducted for data from both 24 and 48-hour time points.
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Relative Expression of IL-6 (pg/mL) 0.6 . Data were further analyzed by grouping strains according to overall LRV-1 status and compared using t tests (B and E). LRV-1-positive and -negative strains of L. V. panamensis (L. V. pan) were compared using t tests (C and F). At 24-hours (A), IL-6 expression differed across strains (**P < .0001), and between LRV-1-positive and negative strains of L. V. braziliensis (*P < .0001). At 48-hours (D), IL-6 expression differed across strains (*P < .0001), and between LRV-1-positive and negative strains of L. V. braziliensis (**P = .0012).
LRV-1 Detection
RNA Extraction
RNA was extracted from cultured cells using QIAmp RNA Mini Kit (Qiagen). An in-column DNase treatment was included in all extractions as per manufacturer's protocol. Extracted RNA was split into 2 batches and stored at -20°C for immediate use and -80°C for longer-term storage. RNA was quantified with Nanodrop spectrophotometer (Thermal Scientific).
Complementary DNA Synthesis and Detection of LRV-1 by qPCR
Complementary DNA (cDNA) was synthesized with 50-300 ng of RNA using Superscript II Reverse Transcriptase and random hexamers (Life Technologies), followed by purification with QIAquick PCR Purification Kit (Qiagen) and eluted with 50 µL of nuclease-free water. Two qPCR assays for detection of LRV-1 were performed with LRV-1 set A and set B primers, respectively, as previously described [25] . Leishmania kinetoplastid membrane protein 11 (kmp11) was used as a quantification and extraction control [25] . Sybr Green qPCR was set up with 1× Sybr Select Master Mix (Life Technologies), 250 nM final concentration of forward and reverse primers, 5 µL of cDNA in a total volume of 20 µL [25] . Amplification was performed in an ABI 7900HT real-time instrument with the following conditions: uracil DNA glycosylase activation at 50°C for 2 minutes, polymerase activation at 95°C for 2 minutes, followed by 45 cycles of 95°C for 15 seconds and 60°C for 1 minute. A dissociation step of 95°C for 15 seconds, 60°C for 15 seconds, and again 95°C for 15 seconds was added at the end to generate a melting curve, which was used to check for the specificity of amplification. In cases where RNA level was too low, a preamplification reaction to increase sensitivity of detection was performed with Perfecta Pre-Amp Supermix (Quanta Biosciences) using 100 ng of cDNA according to manufacturer's protocol with 14 cycles. The reaction was diluted 1:20 and 5 µL of the pre-Amp cDNA was used in subsequent qPCR as above. ATCC 50126 L. V. guyanensis strain MHOM/BR/75/M4147, known to be LRV-1 + , was used as a positive control and RNA from a healthy human individual as negative control. LRV-1 was quantified relative to kmp11 using the 2 -∆∆Ct method [26] .
RESULTS
Clinical and Demographic Data
Five clinical cultures were obtained from male patients with a mean age of 39.8 years (range, 9-80 years) (Supplementary Table 1 ). Three of the 5 clinical cultures were LRV-1 + (LVb + , LVp1 + , and LVp2 + ) and 2 were LRV-1 -(LVp1 -and LVp2 -). All clinical cultures with the exception of LVp2 -were from patients exhibiting a severe phenotype (ie, inflammatory or multifocal as previously defined). All clinical isolates were derived from patients with a travel history to Costa Rica, with the exception of LVb + where the travel history had been to Peru.
Biomarker Data
For Figures 1-6 , letters A-C correspond to measurements at 24 hours whereas letters D-F correspond to measurements at 48 hours.
Th2 Cytokine IL-6
IL-6 Expression
At 24 and 48 hours, peak relative expression of IL-6 differed across strains regardless of LRV-1 status (P < .0001) ( Figure 1A and 1D). Overall, there was no difference in IL-6 expression between LRV-1 + and LRV-1 -strains at 24 hours (P = .72) and 48 hours (P = .49), respectively ( Figure 1B and 1E) . Species stratification revealed no significant difference of LRV-1 status among the L. V. panamensis strains at both 24 hours (P = .43) and 48 hours (P = .29) (Figure 1C and 1F ). IL-6 expression was significantly decreased in the LVb + strain compared with the LVbstrain at both 24 hours (P < .0001) and 48 hours (P = .0012) ( Figure 1A and 1D).
Th1 Cytokines and Chemokines: IL-1β, TNF-α, CCL5, and CXCL10
IL-1β Expression
At 24 and 48 hours, peak relative expression of IL-1β differed across strains (P = .006 and P = .0027, respectively) ( Figure 2A and 2D). There was no difference in expression by LRV-1 status of IL-1β at 24 hours (P = .59) and 48 hours (P = .88), respectively ( Figure 2B and 2E). Species stratification revealed no significant difference in LRV-1 status among the L. V. panamensis strains at both 24 hours (P = .23) and 48 hours (P = .60) ( Figure 2C and 2F). At 48 hours, IL-1β expression was significantly decreased in the LVb + strain compared with the LVb -strain (P = .0015) ( Figure 2D ).
TNF-α Expression
At 24 and 48 hours, peak relative expression of TNF-α differed across strains (P = .007 and P < .0001, respectively) ( Figure 3A and 3D). Overall, LRV-1 + strains showed no difference in relative expression of TNF-α compared with LRV-1 -strains at 24 hours (P = .59) and 48 hours (P = .88), respectively ( Figure 3B and 3E). L. V. panamensis stratification revealed no significant difference by LRV-1 status at both 24 hours (P = .43) and 48 hours (P = .19) ( Figure 3C expression was significantly decreased in the LVb + strain compared with the LVb -strain, respectively (P = .0031 and P = .01) ( Figure 3A and 3D ).
CCL5 Expression
At 24 and 48 hours, peak relative expression of CCL5 differed across strains (P < .0001) ( Figure 4A and 4D) . Overall, LRV-1 + strains revealed no difference in relative expression of CCL5 compared with LRV-1 -strains at 24 hours (P = .66) and 48 hours (P = .71), respectively ( Figure 4B and 4E) . Species stratification revealed no significant difference in LRV-1 status among the L. V. panamensis strains at 24 hours (P = .76); however, a slight reduction in CCL5 expression at 48 hours was observed in the LRV-1 + strains of L. V. panamensis (P = .06) ( Figure 4C and 4F). At 24 and 48 hours, CCL5 expression was not significantly reduced in the LVb + strain compared with the LVb -strain (P = .54 and P = .39) ( Figure 4A and 4D ).
CXCL10 Expression
At 24 and 48 hours, peak relative expression of CXCL10 differed across strains (P < .0001) ( Figure 5A and 5D). Overall, LRV-1 + strains revealed no difference in relative expression of CXCL10 compared to LRV-1 -strains at 24 hours (P = .45) and 48 hours (P = .47), respectively ( Figure 5B and 5E). Species stratification revealed no significant difference in LRV-1 status among the L. V. panamensis strains at both 24 hours (P = .21) and 48 hours (P = .35) ( Figure 5C and 5F). At 24 and 48 hours, CXCL10 expression was significantly decreased in the clinical LVb + strain compared to the LVb -strain, respectively (P = .0003 and P = .0004) ( Figure 5A and 5D ).
Other Biomarkers
IL-4, IL-5, IL-12, iNOS, and IFN-β expression were below levels of detection and could not be quantitated.
Cu-Zn-SOD Expression
SOD Expression
At 24 and 48 hours, peak relative expression of SOD differed across strains (P = .007 and P < .0001) ( Figure 6A and 6D) . Overall, LRV-1 + strains revealed no difference in relative expression of SOD compared to LRV-1 -strains at 24 hours (P = .97) and 48 hours (P = .49), respectively ( Figure 6B and 6E) . L. V. panamensis stratification revealed no significant difference in LRV-1 status at 24 hours (P = .13), however, at 48 hours relative SOD expression was slightly higher in the LRV-1 + L. V. panamensis strains (P = .07) ( Figure 6C and 6F). At 24 hours, SOD expression was significantly higher in the LVb + strain compared with the LVb -strain (P = .04) ( Figure 6A ). This difference was not observed at 48 hours (P = .49) ( Figure 6D ). LRV-1 was first detected in the human pathogen L. V. guyanensis in 1988 from a visitor to Suriname with reported satellite lesions around an ulcer of CL and lymphatic involvement [27] . The same strain passaged through a hamster model produced a phenotype resembling ML [27] . Decades later, numerous reports of LRV-1 in L. V. braziliensis and L. V. guyanensis strains exacerbating disease have highlighted its potential role in accelerating CL to ML. To date, LRV-1 has not been detected in isolates other than New World Leishmania Viannia species. The novel documentation of LRV-1 in strains of L. V. panamensis in this analysis supports that LRV-1 coinfection may be more widespread in Viannia isolates, other than L. V. braziliensis and L. V. guyanensis, than previously recognized. Lately, the correlation of the host immune response relative to LRV-1 status has shed light on "immunophenotypes" that exist, and which can potentially serve as a predictive biomarker of disease severity, thus allowing for therapeutic solutions harnessing both host and parasitic cellular machinery. Using the U937 cell line, which has a long precedent of modeling human macrophages in vitro, we were able to model successful L. V. species infection that elicits both proinflammatory cytokines and chemokines. To our knowledge, this is the first report of LRV-1 detection in strains of L. V. panamensis, a strain that is historically viewed as less virulent compared to L. V. braziliensis. Furthermore, 3 of 4 LRV-1 + clinical isolates used in this study were derived from patients with an inflammatory/ severe phenotype, characterized by ulcer erythema, purulence, and pain, along with possible lymphatic involvement, which complicates the treatment course of ATL by necessitating systemic therapy (eg, oral miltefosine or intravenous liposomal amphotericin). It is unknown at this point whether LRV-1 could potentially serve as an important marker of more invasive or complicated disease, which would have direct implications for treatment; however, the notion is tantalizing and thus warrants further investigation.
The expression of Th1/Th2 biomarkers and SOD did not differ by LRV-1 status among isolates of L. V. panamensis. However, a slight increase in SOD expression was observed at 48 hours alongside a slight decrease of CCL5 response in LRV-1 + isolates, which could point to parasitic persistence given reduced killing of the parasite in the macrophage vacuole. Cu-Zn-SOD is an enzyme that protects cells from the constant oxidative challenge posed by normal oxidative metabolism [13] . Upon infection, macrophages produce ROS to effectively kill the parasite. It has been hypothesized that LRV-1 released from dead parasites in infected macrophages might upregulate the production of Cu-Zn-SOD by manipulation of arginase I, thereby decreasing the concentration of free radical available for parasite clearance allowing it to persist in the vacuole [13] . The LVb + isolate produced significantly lower levels of the Th1 cytokines IL-1β, CXCL10, and TNF-α as well as Th2 IL-6, compared with LVb -, and significantly higher levels of SOD, resulting in an inversed mixed Th1/Th2 phenotype compared to what has been observed in other mouse and human models [8, 10, 11, 28, 29] . Given that a robust Th1 response is highly correlated to clinical cure and immunological control of infection [1, 10] , the Th2-biased response observed here, coupled with parasitic persistence through the upregulation of SOD, highlights a potentially severe immunophenotype, which could also explain the possibility of relapse in patients months to years following clinical cure.
Previous studies have used human metastatic strains of L. V. guyanensis and L. V. braziliensis to infect mice or human peripheral blood mononuclear cells (PBMCs) to understand the overall Th1/Th2 paradigm. The disadvantage to studying ML in mice models is the lack of nasopharyngeal pathology compared with what is seen in humans, which leads to misrepresentation of inflammation-mediated tissue damage in these animals [30] . The use of the U937 cell line in our investigation mimics the immunological profile of what might be observed in a proximate human PBMC model, and is more representative of human ATL than a murine model. The differences in biomarker expression observed by LRV-1 status among isolates of L. V. braziliensis, although opposite to what has been observed in highly regarded murine models, illuminate the immunological effects that could explain clinical phenotype, and even downstream potential treatment outcomes [8, 10, 11, 28, 29] . Finally, a more robust immunological analysis using more clinical isolates, high-sensitivity EIA kits or a multiplex bead-based platform such as Luminex, and use of human skin tissue models could provide more insight into the mechanistic nature of LRV-1 given the limited number of clinical isolates and proinflammatory biomarkers evaluated in this study. to better understand the role of LRV-1 in manipulating host immune responses. The novel detection of LRV-1 in strains of L. V. panamensis suggests further evaluation of strains not previously known to harbor the double-stranded RNA virus. Our data support that LRV-1 may be an important prognostic biomarker in ATL, which could have potential implications for treatment stratification by severity of disease. Understanding the potential role of LRV-1 in clinical relapse and progression of CL to ML warrants further prospective investigation.
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